Nuvo began exploring formulations to improve upon the original Pennsaid^® formulation in late 2004. The Corporation has conducted preliminary testing of several potential improved versions of Pennsaid^®, currently referred to as NRI-1004 or Pennsaid Plus. While no clinical trials of this product have taken place to date, in vitro testing has indicated that NRI-1004 can significantly increase the transport of diclofenac, the active therapeutic drug in both Pennsaid^® and NRI-1004, through the skin. The development of NRI-1004 is an important step in the Corporation’s plan to develop a family of topically applied transdermally delivered drugs with applications across serveral of therapeutic areas.

NRI-1004 is designed to provide users with the efficacy of existing Pennsaid^® , with less frequent dosing and increased ease of application. Patent applications for NRI-1004 have been filed and a pivotal phase III trial for the product is planned.